# NCT01287741 (NCT01287741)

> A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01287741
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Hoffmann-La Roche
- Conditions: Diffuse Large B-Cell Lymphoma
- Interventions: Rituximab; Obinutuzumab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone
- Enrollment: 1418
- Primary outcome: Median Time to Progression-Free Survival (PFS), Investigator-Assessed

## Commentary we found

- Podcasts: 3
- X threads: 3
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct01287741

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01287741", "email": "<work email>"}; the inbox owner confirms by the emailed link.